Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia

Documenti analoghi

• Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
  di: Simioni, Carolina, et al.
  Pubblicazione: (2014)
• Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia
  di: Simioni, Carolina, et al.
  Pubblicazione: (2016)
• Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
  di: Alameen, Ayman A.M., et al.
  Pubblicazione: (2016)
• The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
  di: Simioni, Carolina, et al.
  Pubblicazione: (2015)
• PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines
  di: Ultimo, Simona, et al.
  Pubblicazione: (2017)